News and Announcements
Biorithm selected for MedTech Innovator Asia Pacific Accelerator cohort 2021
- Published July 12, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Biorithm is thrilled to announce that our company has been selected to be part of the 2021 MedTech Innovator Asia Pacific Cohort.
MedTech Innovator is a medical technology global showcase and accelerator for innovative medical devices, digital health, and diagnostic companies. Every year, MedTech Innovator selects the most outstanding 20 medical technology startups across Asia Pacific region to participate in this program with the aim to help them grow and transform the healthcare system.
Through this program, Biorithm is expecting to have access to personalized mentorship and coaching to help with the commercialization of the Femom solution, visibility to healthcare investors, and broad exposure to leading players in the medical technology space.
Participants will also benefit from customised virtual curriculum and have access to webinar sessions from a parallel US program providing information regarding accessing and operating in the US and EU regions, which are part of the market targeted by Biorithm. In addition, the MedTech Innovator Asia Pacific Cohort startups will compete for up to US $300,000 in cash and awards.
About Biorithm
Founded by doctors and engineers, Biorithm is a medical technology start-up spun-off from Nanyang Technological University in Singapore. We believe that comprehensive maternal healthcare should leverage the power of digital health and advanced sensors to address individual patient and clinicians needs, enhance data-driven decisions, and complication prevention, and provide access to affordable and preventive care.
Biorithm has developed Femom, a cutting-edge analytic software together with medical-grade abdominal ECG wearable designed for remote monitoring of maternal and fetal physiological parameters. Our Femom solution enables clinicians to gain new insights into the health of the mother and baby whilst offering expecting mothers better access to healthcare, convenience, and more information about their pregnancy to identify early signs of complications.
Femom has been designed and developed in close collaboration with women, clinicians, and university hospitals.
Company Updates
The asset class where the market has no vote
Litigation funding returns are decided in a courtroom, not a cycle. Knightsbridge’s Head of Capital is careful to call that a different risk rather than a lower one, and his answer to it is spread, not concentration. Most alternative assets still answer to something. Property answers to rates. Private credit answers to defaults. Even the […]
The listing fee vendors pay whether the house sells or not
Australia’s property portals collect more than $2 billion a year while national listings sit flat. An Australian-built AI platform is targeting the economics, not just the interface. An Australian vendor listing a home pays a vendor-paid advertising fee on top of agency commission. Rama Dwarapudi, Founder and Chief Executive Officer of RealSearch, puts a typical […]
Reinventing the Condom: How an Australian Deep-Tech Startup Plans to Disrupt a $12 Billion Market
For more than half a century, the global condom industry has remained fundamentally unchanged, constrained by standard materials like latex and solid synthetic polymers. Despite widespread consumer demand for better alternatives, product design has treated the device strictly as a mechanical barrier, sacrificing feel for function. Sydney-based Eudaemon Technologies is setting out to upend that […]
Backed By Leading Investment Groups and Family Offices
